Want to see JP:190A full AI Analyst Report?
190A Stock Chart & Stats
¥108.00
-¥9.00(-2.81%)
At close: 4:00 PM EST
¥108.00
-¥9.00(-2.81%)
Day’s Range― - ―
52-Week Range¥66.00 - ¥220.00
Previous CloseN/A
Volume2.20M
Average Volume (3M)565.44K
Market Cap
¥5.81B
Enterprise Value¥2.59B
Total Cash (Recent Filing)¥2.45B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta0.35
Next Earnings
Jul 15, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-20.68
Shares Outstanding76,392,400
10 Day Avg. Volume542,310
30 Day Avg. Volume565,443
Financial Highlights & Ratios
PEG Ratio0.42
Price to Book (P/B)5.07
Price to Sales (P/S)0.00
P/FCF Ratio-6.70
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetHaving no reported debt materially lowers insolvency risk and preserves financial flexibility for a pre-revenue/early-stage biotech. Over the next 2–6 months this reduces bankruptcy tail risk, improves ability to pursue equity, partner-funded deals, or licensing without interest obligations that could strain cash flow.
Demonstrated Prior Revenue/profitabilityThe company produced revenue and positive net income in 2023, evidencing commercial or milestone capability. That prior commercialization experience reduces structural execution risk versus never‑revenue peers and suggests the underlying platform or assets can support revenue if development or partnerships reaccelerate.
Focused Oncology Small-molecule R&DA clear, specialized business model concentrating on small‑molecule oncology therapeutics creates sustained strategic focus. This specialization can foster deep scientific capabilities, targeted asset prioritization and stronger partnership appeal, improving long-term probability of successful candidate advancement and licensing.
Bears Say
Zero Revenue And Widening LossesA return to zero reported revenue and a deep 2025 net loss indicate the company currently lacks internal revenue generation to fund operations. Over months this undermines margin sustainability and shifts reliance to external financing or partner deals, heightening dilution and execution risk for ongoing R&D programs.
Sustained Negative Operating Cash FlowPersistent, large negative operating cash flows show real cash burn rather than accounting losses. This depletes reserves, pressures runways for trials and discovery, and makes the company structurally dependent on new capital or partner financing—an enduring constraint on program advancement and negotiating leverage.
Eroding Equity And Very Negative ROEMaterial erosion of shareholders' equity and a deeply negative ROE signal a weakened capital base. Over a multi‑month horizon this reduces the buffer against future losses, increases probability of dilutive fundraising on unfavourable terms, and constrains the firm's ability to absorb setbacks in clinical development.
Chordia Therapeutics Inc. News
190A FAQ
What was Chordia Therapeutics Inc.’s price range in the past 12 months?
Chordia Therapeutics Inc. lowest stock price was ¥66.00 and its highest was ¥220.00 in the past 12 months.
What is Chordia Therapeutics Inc.’s market cap?
Chordia Therapeutics Inc.’s market cap is ¥5.81B.
When is Chordia Therapeutics Inc.’s upcoming earnings report date?
Chordia Therapeutics Inc.’s upcoming earnings report date is Jul 15, 2026 which is in 11 days.
How were Chordia Therapeutics Inc.’s earnings last quarter?
Chordia Therapeutics Inc. released its earnings results on Apr 10, 2026. The company reported -¥4.71 earnings per share for the quarter, missing the consensus estimate of N/A by -¥4.71.
Is Chordia Therapeutics Inc. overvalued?
According to Wall Street analysts Chordia Therapeutics Inc.’s price is currently Overvalued.
Does Chordia Therapeutics Inc. pay dividends?
Chordia Therapeutics Inc. does not currently pay dividends.
What is Chordia Therapeutics Inc.’s EPS estimate?
Chordia Therapeutics Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Chordia Therapeutics Inc. have?
Chordia Therapeutics Inc. has 76,392,400 shares outstanding.
What happened to Chordia Therapeutics Inc.’s price movement after its last earnings report?
Chordia Therapeutics Inc. reported an EPS of -¥4.71 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.775%.
Which hedge fund is a major shareholder of Chordia Therapeutics Inc.?
Currently, no hedge funds are holding shares in JP:190A
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Chordia Therapeutics Inc.
Chordia Therapeutics Inc., a biotech company, engages in research and development of anti-cancer drugs that targets RNA deregulation stress in Japan. It develops CLK CTX-712, a CLK inhibitor, which is Phase 1 clinical trial for the treatment of relapsed or refractory malignant cancers.; CTX-177, a small-molecule inhibitor of MALT1; CDK12 inhibitor CTX-439; and GCN2 inhibitor CRD-1968099. Chordia Therapeutics Inc. was incorporated in 2017 and is based in Fujisawa, Japan.
Technical Analysis
Pharmarise Holdings Corp.
―
COSMOS Pharmaceutical Corporation
―
Tsubota Laboratory Incorporated
―
Shinnihonseiyaku Co., Ltd.
―
Heartseed, Inc.
―